BioMarin Pharmaceutical (NASDAQ:BMRN) Stock Sees Unusually High Call Option Buying

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) was the recipient of some unusual options trading on Tuesday. Stock traders purchased 3,961 call options on the company. This is an increase of approximately 228% compared to the average volume of 1,206 call options.

Institutional Investors Weigh In On BioMarin Pharmaceutical

Institutional investors have recently made changes to their positions in the company. Kestra Advisory Services LLC increased its holdings in BioMarin Pharmaceutical by 23.4% in the 3rd quarter. Kestra Advisory Services LLC now owns 4,520 shares of the biotechnology company’s stock worth $271,000 after acquiring an additional 857 shares in the last quarter. Bfsg LLC acquired a new stake in BioMarin Pharmaceutical during the 3rd quarter worth about $1,052,000. Oregon Public Employees Retirement Fund lifted its position in BioMarin Pharmaceutical by 0.5% during the third quarter. Oregon Public Employees Retirement Fund now owns 40,117 shares of the biotechnology company’s stock valued at $2,407,000 after purchasing an additional 200 shares during the period. Bank Julius Baer & Co. Ltd Zurich purchased a new position in shares of BioMarin Pharmaceutical during the 3rd quarter valued at approximately $186,000. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of BioMarin Pharmaceutical in the third quarter valued at approximately $705,000. Hedge funds and other institutional investors own 98.71% of the company’s stock.

More BioMarin Pharmaceutical News

Here are the key news stories impacting BioMarin Pharmaceutical this week:

• Positive Sentiment: BioMarin reported third-quarter revenue of $1.025 billion, up 32% year over year and in line with expectations. Adjusted EPS was $0.23, well above the consensus estimate for a loss of roughly $0.08–$0.09. Growth was led by a 44% increase in metabolic-condition revenue and a 12% rise in skeletal-condition revenue. BioMarin Reports Third Quarter 2026 Financial and Operating Results
• Positive Sentiment: The company added a new investigational Fabry disease asset to its clinical portfolio and reported a May 30, 2027 PDUFA action date for VOXZOGO in hypochondroplasia, supporting BioMarin’s longer-term growth story.
• Positive Sentiment: Options activity was notably bullish, with traders purchasing 3,961 call options—about 228% above typical call volume—suggesting increased speculative interest in a potential rebound.
• Neutral Sentiment: Analyst opinion remains mixed. Citi reiterated a Buy rating, while Royal Bank of Canada maintained a Sector Perform rating, indicating that near-term execution concerns are balanced against BioMarin’s pipeline potential.
• Negative Sentiment: BioMarin lowered its 2026 adjusted EPS guidance to $2.80–$3.10, below the $3.32 analyst consensus, and issued revenue guidance of $3.8 billion–$3.9 billion versus the $3.9 billion consensus. Management cited order-timing uncertainty and charges related to two acquired in-process research programs. BioMarin Q3 2026 Results and Guidance
• Negative Sentiment: Royal Bank of Canada lowered its BMRN price target from $62 to $60 while retaining its Sector Perform rating, reinforcing investor concerns about limited near-term upside.

Analyst Ratings Changes

BMRN has been the subject of several recent analyst reports. Morgan Stanley dropped their price objective on shares of BioMarin Pharmaceutical from $124.00 to $122.00 and set an “overweight” rating for the company in a report on Wednesday, October 21st. Royal Bank Of Canada lowered their target price on BioMarin Pharmaceutical from $62.00 to $60.00 and set a “sector perform” rating for the company in a research note on Tuesday. Piper Sandler increased their price objective on shares of BioMarin Pharmaceutical from $88.00 to $90.00 and gave the stock an “overweight” rating in a report on Tuesday, September 1st. HC Wainwright reiterated a “neutral” rating and issued a $60.00 price objective on shares of BioMarin Pharmaceutical in a research report on Tuesday. Finally, JPMorgan Chase & Co. upped their target price on shares of BioMarin Pharmaceutical from $86.00 to $87.00 and gave the company an “overweight” rating in a research report on Tuesday, October 20th. Three investment analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, six have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, BioMarin Pharmaceutical has an average rating of “Moderate Buy” and a consensus price target of $88.09.

BioMarin Pharmaceutical Trading Down 4.2%

NASDAQ:BMRN traded down $2.39 during mid-day trading on Tuesday, hitting $55.05. 1,527,316 shares of the company’s stock were exchanged, compared to its average volume of 2,110,063. The company has a current ratio of 2.39, a quick ratio of 1.32 and a debt-to-equity ratio of 0.56. The firm has a market capitalization of $10.66 billion, a P/E ratio of 148.78, a PEG ratio of 0.61 and a beta of 0.22. The company has a 50 day simple moving average of $60.43 and a 200-day simple moving average of $58.46. BioMarin Pharmaceutical has a fifty-two week low of $49.26 and a fifty-two week high of $70.98.

BioMarin Pharmaceutical (NASDAQ:BMRN) last announced its quarterly earnings results on Monday, November 2nd. The biotechnology company reported $0.23 EPS for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.31. BioMarin Pharmaceutical had a net margin of 2.14% and a return on equity of 5.32%. The business had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1.02 billion. During the same quarter in the previous year, the business posted $0.12 EPS. BioMarin Pharmaceutical’s quarterly revenue was up 32.0% on a year-over-year basis. As a group, research analysts expect that BioMarin Pharmaceutical will post 2.59 earnings per share for the current year.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc is a biotechnology company focused on developing and commercializing therapies for serious and life-threatening rare diseases. The company’s research and development efforts center on genetic and metabolic disorders, where patient populations are often small and treatment options are limited.

BioMarin’s marketed products include Voxzogo (vosoritide) for children with achondroplasia and open growth plates, Palynziq (pegvaliase) and Kuvan (sapropterin dihydrochloride) for phenylketonuria, Brineura (cerliponase alfa) for late-infantile neuronal ceroid lipofuscinosis type 2, Vimizim (elosulfase alfa) for Morquio A syndrome, and Naglazyme (galsulfase) for mucopolysaccharidosis VI.